Veradermics, INC

Veradermics announces positive Phase 2 results for VDPHL01 in female hair loss, completes enrollment for a key Phase 2/3 trial, and reports a strong cash position extending operational runway to 2030.

Veradermics, Inc. announced positive topline results from its Phase 2 clinical trial (Study 207) for VDPHL01, an oral extended-release minoxidil formulation, in females with mild-to-moderate pattern hair loss.

Veradermics announced positive Phase 2/3 results for its pattern hair loss treatment VDPHL01, bolstered by a strong cash position from recent financing.

Veradermics, Incorporated has closed a $30 million private placement of pre-funded warrants to institutional investors.

Veradermics, Incorporated announced a preliminary unaudited cash and marketable securities balance of $390.8 million as of March 31, 2026.

Veradermics, Inc. announced positive topline results from its Phase 2/3 clinical trial (Study 302) evaluating VDPHL01 for mild-to-moderate pattern hair loss in males, meeting all primary and key secondary endpoints.

Veradermics, Inc. announced positive topline data for its VDPHL01 drug in pattern hair loss trials and significant capital raises, while also detailing substantial operating expenses and future funding needs.

Veradermics, Inc. announced positive topline data from its Study 302 evaluating VDPHL01 for pattern hair loss, showing statistically significant improvements in hair count and patient-reported outcomes.

Montanova Capital, Llc and 3 others reported changes in beneficial ownership of Veradermics, Inc common stock on August 19, 2026.

Timothy August Durso, Chief Technical Officer of Veradermics, Inc, sold 43,500 shares of common stock on August 17, 2026.

Reid Alexander Waldman, Chief Executive Officer and a Director of Veradermics, Inc, sold 67,500 shares of common stock on August 17, 2026.

John W Childs, a Director of Veradermics, Inc, sold 100,000 shares of common stock on August 12, 2026.

Veradermics, Inc. secures a $30 million investment from Suvretta Capital through a private placement of pre-funded warrants.

Veradermics Director John W. Childs filed an amended Form 4 to correct the nature of indirect beneficial ownership for 294,117 common shares.

Veradermics, Incorporated has filed a Form S-1 registration statement to allow for the resale of up to 16,772,058 shares of common stock and 300,000 shares underlying pre-funded warrants by selling stockholders.

Veradermics, Inc. has filed to increase its initial public offering by approximately $56.8 million, bringing the total potential aggregate offering to over $442 million.

Veradermics, Incorporated has filed a registration statement for a follow-on offering of 3,350,000 shares of common stock or pre-funded warrants to fund commercialization and operations.

Montanova Capital, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen have filed an amendment to their Schedule 13D, reporting changes in their beneficial ownership of Veradermics, Incorporated common stock.

SR One Capital Management and affiliated entities have filed an amendment to their Schedule 13D, reporting a sale of Veradermics, Inc. common stock and adjusting their beneficial ownership.

Suvretta Capital Management and its affiliates have acquired 300,000 pre-funded warrants in Veradermics, Inc., strengthening their 9.9% stake in the company.

Longitude Capital Partners and associated entities disclosed a 11.3% beneficial ownership stake in Veradermics, Incorporated.

Seven Fleet Master Fund LP has acquired 80,000 shares of Veradermics, Inc., representing a 0.2% ownership stake.

Longitude Capital and its affiliates, including board member Patrick G. Enright, reported a 12.5% beneficial ownership in Veradermics, Incorporated following recent IPO purchases and preferred stock conversions.

Viking Global Investors LP and associated entities filed an amendment to their Schedule 13G, reporting a 4.5% beneficial ownership stake in Veradermics, Inc. following the retirement of David C. Ott.

Citadel entities, including Citadel Advisors LLC and Kenneth Griffin, have reported beneficial ownership of 4.5% of Veradermics, Incorporated's common stock.

Viking Global Investors LP and its affiliates have reported a 5.8% beneficial ownership stake in Veradermics, Inc. following the company's recent initial public offering.